Merck Issues 2018/2019 Corporate Responsibility Report
October 08 2019 - 8:00AM
Business Wire
Report Illustrates Merck’s Approach to
Long-Term Sustainability for Business and Society
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today issued its 2018/2019 Corporate Responsibility Report.
The report highlights the company’s performance and progress in its
four corporate responsibility priority areas of Access to Health,
Employees, Environmental Sustainability and Ethics &
Values.
“Operating responsibly is at the heart of our ability to deliver
sustainable impact and long-term value for our business and
society,” said Kenneth C. Frazier, Merck chairman and chief
executive officer.
The report reflects the company’s belief that serving social
good and achieving business success are deeply interdependent.
Merck is tackling some of society’s biggest health challenges and
joining forces with the global community to help realize the United
Nations’ Sustainable Development Goals.
Highlights from this year’s report include:
- Merck has reaffirmed its commitment to provide supply of the
investigational Ebola Zaire vaccine as part of international
response efforts to address Ebola outbreaks. The vaccine has been
administered to more than 200,000 people in Central Africa.
- Merck for Mothers, a $500 million initiative that aims to
reduce maternal mortality, has now reached more than 9 million
women in 48 countries.
- With a continued focus on science, the company’s research in
oncology is providing hope to a growing number of patients with
development programs across more than 30 tumor types.
- As part of its commitment to the health and wellbeing of
employees, Merck offers programs, resources and tools to 99% of its
global workforce with the goal of reaching 100% in 2020.
- Merck continues to make progress on its environmental goals. An
agreement with Invenergy Wind Development will help Merck reduce
its GHG emissions to help combat climate change.
- New laboratories, offices and major renovations are designed to
meet LEED Silver or the comparable country standard. The China Head
Office is certified as LEED Gold and new South San Francisco Office
was built to LEED Gold Standards.
- In 2018 and again in 2019, Merck was honored by the American
Chemistry Society (ACS) as one of five winners of the Green
Chemistry Challenge Awards.
- In 2018, the company signed on to Paradigm for Parity®,
furthering its commitment to gender equality. In 2019, it joined
P&G and Women Deliver to introduce the Deliver for Good
Business Ally Network to strengthen collaboration within the
private sector and to promote critical investments in girls and
women.
Learn more about Merck’s approach to corporate responsibility
and progress on key initiatives in the 2018/2019 Corporate
Responsibility Report.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us on Twitter, Facebook,
Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2018
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191008005058/en/
Media Contacts: Pam Eisele (267) 305-3558
Carol Richardson (908) 740-1526
Investor Contacts: Peter Dannenbaum (908) 740-1037
Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024